Insider · CIK 0001841401
Bryan Wahl
Files at TARS (Tarsus Pharmaceuticals, Inc.). First filing Mar 19, 2026, latest Mar 19, 2026.
Bryan Wahl files SEC Form 4 as officer at TARS (Tarsus Pharmaceuticals, Inc.). Since Mar 19, 2026, Bryan Wahl has reported 0 open-market buys worth $0 and 1 open-market sell worth $850k, the latest filed on Mar 19, 2026.
A track record needs three past buys with six months of prices behind them; Bryan Wahl has 0, so none is measured yet.
The newest scored trade: sold $850k of TARS on Mar 17, 2026, filed Mar 19, 2026, scored 58 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $850k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TARS: Tarsus Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | Tarsus Pharmaceuticals, Inc. | $850k 12,440 shares | -16% | +80% from low-15% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 3,084 0.01% of outstanding | $155k | Mar 20, 2025 | $309k |
| Mar 19, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 3,261 0.01% of outstanding | $155k | Mar 19, 2025 | $155k |
| Mar 18, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 3,341 0.01% of outstanding | $155k | Mar 18, 2025 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,084 | $69.42 | $284k | 72,315 | Mar 19, 2026 |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,125 | $68.71 | $283k | 68,190 | Mar 19, 2026 |
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,231 | $67.00 | $283k | 63,959 | Mar 19, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +24,236 | - | - | 76,399 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -4,790 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -7,248 | $0.00 | $0 | 7,249 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -7,176 | $0.00 | $0 | 14,351 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -5,022 | $0.00 | $0 | 15,067 | Mar 17, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +27,310 | $0.00 | $0 | 27,310 | Mar 9, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +17,161 | $0.00 | $0 | 17,161 | Mar 9, 2026 |
Questions about Bryan Wahl
Answered from the filings on this page, as of the latest one.
Is Bryan Wahl buying or selling?
In the last 12 months Bryan Wahl reported 0 open-market buys worth $0 and 1 open-market sell worth $850k on SEC Form 4; the latest was sold $850k of TARS on Mar 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Bryan Wahl's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Bryan Wahl has 0.
Where does Bryan Wahl file Form 4?
Bryan Wahl has filed Form 4 at TARS (Tarsus Pharmaceuticals, Inc.) as General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.